中国医院药学杂志2024,Vol.44Issue(16) :1960-1962.DOI:10.13286/j.1001-5213.2024.16.19

肾移植患者感染COVID-19引起他克莫司血药浓度升高1例

Infection with COVID-19 in kidney transplant recipient with an elevated level of tacrolimus:one case report

邵佳 陈凡 任海霞
中国医院药学杂志2024,Vol.44Issue(16) :1960-1962.DOI:10.13286/j.1001-5213.2024.16.19

肾移植患者感染COVID-19引起他克莫司血药浓度升高1例

Infection with COVID-19 in kidney transplant recipient with an elevated level of tacrolimus:one case report

邵佳 1陈凡 2任海霞2
扫码查看

作者信息

  • 1. 天津市第一中心医院药学部,天津 300192;天津市第一中心医院国家卫生健康委员会危重病急救医学重点实验室,天津 300192
  • 2. 天津市第一中心医院药学部,天津 300192
  • 折叠

摘要

肾移植患者长期使用免疫抑制剂,其感染COVID-19的风险增加.该例报告中,肾移植患者长期使用他克莫司(tacrolimus,TAC)预防排斥反应,感染COVID-19引起TAC血药浓度异常升高.通过文献复习,对造成TAC血药浓度升高的病理因素以及因TAC血药浓度升高导致的肝损伤、肾损伤等不良反应进行分析,为今后感染COVID-19的肾移植患者病理因素分析,以及TAC血药浓度异常引起的不良反应防治提供参考.

Abstract

An elevated risk of COVID-19 is due to long-term use of immunosuppressants in kidney transplant(KT)recipients.In this report,one patient received tacrolimus(TAC)for a long time to prevent rejection.And COVID-19 caused an abnormal blood drug concentration of TAC.Patho-logical factors and adverse heptorenal reactions leading to an elevated level of TAC were examined through a literature review.It provided references for analyzing pathological fac-tors in COVID-19 KT recipients and preventing adverse reac-tions of an abnormal blood concentration of TAC.

关键词

肾移植/他克莫司/COVID-19

Key words

kidney transplantation/tacrolimus/COVID-19

引用本文复制引用

出版年

2024
中国医院药学杂志
中国药学会

中国医院药学杂志

CSTPCD北大核心
影响因子:1.198
ISSN:1001-5213
段落导航相关论文